by Elec23 | Jun 18, 2026 | News&events, VisMederi
VisMederi and CEVAC, a Belgian vaccine research center comprising a Clinical Trial Unit and an Immunomonitoring Laboratory, have signed a Memorandum of Understanding (MoU) to strengthen their collaboration in vaccine clinical trials, a core area of expertise for both...
by Elec23 | May 26, 2026 | News&events, VisMederi
VisMederi and KingMylab have announced the signing of a strategic collaboration agreement aimed at strengthening testing and analytical services for vaccine and biologics clinical trials. The partnership combines KingMylab’s expertise in central laboratory...
by Elec23 | Apr 11, 2025 | News&events
We are proud to announce that VisMederi has once again been included in the Financial Times FT 1000 ranking, placing 483rd among Europe’s fastest-growing companies in 2025. The eighth annual list, compiled in collaboration with Statista, recognises companies that have...
by Elec23 | Apr 9, 2025 | News&events
VisMederi’s R&D Department, in collaboration with the University of Siena, University of Palermo, and University of Bari, has developed and validated a new high-throughput neutralization assay for human Metapneumovirus (hMPV) A and B. This pivotal work aims to...
by Elec23 | Feb 24, 2025 | News&events
VisMederi has expanded its testing portfolio with cutting-edge pseudo-viral platforms, which are critical tools for examining immunogenicity and developing vaccines against emerging infections. These new technologies enable us to test immune responses in a safe and...
